Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Boston Scientific Corporation    BSX

News SummaryMost relevantAll newsSector newsTweets

Boston Scientific Corporation : BSX, ABT, ZMH, and ETRM Under StockCall’s Microscope

share with twitter share with LinkedIn share with facebook
share via e-mail
05/02/2013 | 02:00pm CET

StockCall.com Provides Stock Research on Boston Scientific Corp., Abbott Laboratories, Zimmer Holdings Inc., and EnteroMedics Inc.

New York City, New York -- (May 02, 2013)

The Supreme Court, last year, upheld the Affordable Care Act (ACA), which is the biggest overhaul of the healthcare industry in decades. While the healthcare industry has generally supported ACA, some features of the act have faced criticism. One such feature is the 2.3% tax on gross U.S. sales of medical devices. Medical appliances & equipment makers say that the tax will lead to higher costs for them, hurting innovation. While the Senate voted in favor of repealing the 2.3% tax, it is unlikely that the tax will be repealed. Shares of medical appliances & equipment companies ended mostly lower on Wednesday, tracking losses in the broad market. Among the major movers were Boston Scientific Corporation (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Zimmer Holdings Inc. (NYSE: ZMH), and EnteroMedics Inc. (NASDAQ: ETRM). StockCall has released full comprehensive research on BSX, ABT, ZMH, and ETRM and these free technical analyses can be downloaded by signing up at


Shares of Boston Scientific Corporation fluctuated between gains and losses on Wednesday before finishing the day flat at $7.49 on volume of 12.95 million. Shares of the company have traded sideways this week. However, year-to-date, the stock has had an excellent run, jumping more than 30.70% as compared to a gain of nearly 11% for the S&P 500. BSX?s shares are currently trading nearly 5.80% below their 52-week high. Free technical analysis on BSX available by signing up at


Shares of Abbott Laboratories edged lower in Wednesday?s trading session, however, the losses were limited. The stock ended the day 0.08% lower at $36.89 on volume of 5.46 million after trading between $36.62 and $37.20. Despite the pullback, Abbott?s shares are up nearly 1.20% for the week. The stock has gained more than 18.50% so far in 2013, outperforming the S&P 500. However, shares of ABT have been struggling to break through $37.50 resistance level. The stock is currently trading well above its 50-day and 200-day moving averages. Register today and access the free research on ABT at


Zimmer Holdings Inc.?s shares also slipped in trading on Wednesday, tracking losses in the broad market. The stock closed 1.50% lower at $75.30 on volume of 617,800. Despite the pullback, the company?s shares are currently trading close to their 52-week high of $77.53. Shares of ZMH have been facing resistance at around $76.50. The stock currently has strong support at around $73. Zimmer?s shares are currently trading well above their 50-day and 200-day moving averages which suggests that market sentiment is bullish on the stock. The positive trend is further confirmed by recent volume activity. The free report on ZMH can be downloaded by signing up now at


Shares of EnteroMedics Inc. tumbled in Wednesday?s trading session after the company reported its financial results for the first quarter. The stock closed 9.59% lower at $0.868 on above average volume of 601,300 after touching an intra-day low of $0.86. Shares of ETRM are currently trading close to their 52-week low of $0.81. Year-to-date, the stock has now fallen nearly 69%. Most of the losses came in mid-February when the stock saw a huge sell-off. EnteroMedics? shares have now slipped below their 50-day moving average. Free report on ETRM can be accessed by registering at


About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at


Contact Person:

William T. Knight

Email: [email protected]

Contact Number: (646) 396-9857 (9:00 am EST ? 01:30 pm EST)

© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
11/17 BOSTON SCIENTIFIC CORP : Change in Directors or Principal Officers, Financial St..
11/17 BOSTON SCIENTIFIC : The Christ Hospital First to Offer New Device to Predict Hea..
11/14 BOSTON SCIENTIFIC : $165,560 Federal Contract Awarded to Boston Scientific
11/14 Air Pollution Linked to Mortality from Kidney, Bladder Cancers Could Warrant ..
11/13 BOSTON SCIENTIFIC : To Participate In Piper Jaffray 29th Annual Healthcare Confe..
11/08 BOSTON SCIENTIFIC : New Societal Guidelines Recommend Subcutaneous Implantable C..
11/08 BOSTON SCIENTIFIC : To Participate In Stifel 2017 Healthcare Conference
11/08 BOSTON SCIENTIFIC : Prosthetics - Portland - BOSTON SCIENTIFIC - Pay 648Q8XXXX
11/08 BOSTON SCIENTIFIC : 65-- Prosthetics - Portland - BOSTON SCIENTIFIC - Pay 648Q8X..
11/06 BOSTON SCIENTIFIC : To Participate In 26th Annual Credit Suisse Healthcare Confe..
More news
News from SeekingAlpha
11/17 BUY EDWARDS LIFESCIENCES : Weak Third-Quarter Performance Is Just A Blip On A Lo..
11/13 STRYKER : Growth In 2018
11/08 GENERAL ELECTRIC : Speculation Runs Rampant Ahead Of Investor Update
11/03 YOUR DAILY PHARMA SCOOP : Timing Synergy Trade, Valeant's Vyzulta Approved, Seat..
11/02 Heart stents fail to ease chest pain - NYT
Financials ($)
Sales 2017 8 995 M
EBIT 2017 2 159 M
Net income 2017 1 176 M
Debt 2017 5 117 M
Yield 2017 -
P/E ratio 2017 35,89
P/E ratio 2018 27,17
EV / Sales 2017 4,88x
EV / Sales 2018 4,41x
Capitalization 38 807 M
Duration : Period :
Boston Scientific Corporat Technical Analysis Chart | BSX | US1011371077 | 4-Traders
Technical analysis trends BOSTON SCIENTIFIC CORPORAT
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 32,0 $
Spread / Average Target 13%
EPS Revisions
Michael F. Mahoney Chairman, President & Chief Executive Officer
Edward Mackey Executive Vice President-Operations
Daniel J. Brennan Chief Financial Officer & Executive Vice President
Ian Meredith Global Chief Medical Officer & Executive VP
Nelda J. Connors Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DANAHER19.86%64 900
ROYAL PHILIPS14.34%36 778
ILLUMINA63.25%30 517